FDA approves Gazyva for primary membranous nephropathy
The agency authorized obinutuzumab injection to induce remission of proteinuria in adults with the kidney disease who face risk of progression.
The FDA has approved Gazyva (obinutuzumab) injection to induce remission of proteinuria in adults with primary membranous nephropathy at risk of disease progression.1
The source material does not specify the exact date of approval, the dosing regimen, clinical trial results, or pricing details. Readers should consult the full FDA record for additional specifics not captured in this summary.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.